SGF Winter Edition 2020 Private Luncheon with Genprex in Paris

Hotel Regina Louvre, Place des Pyramides, Paris, France

Genprex is a clinical-stage gene therapy company utilizing a unique, non-viral proprietary platform designed to deliver tumor suppressor genes to cancer cells. Genprex actively trades on the Nasdaq Capital Market and has a $136 million market cap (as of 2/18/20): Genprex’s lead product candidate, Oncoprex™ immunogene therapy, utilizes targeted therapy and immunotherapy for non-small cell lung cancer (NSCLC). Genprex’s Oncoprex, in combination with AstraZeneca’s Tagrisso® (their best-selling product and on pace for $3B+ in 2019 sales), was awarded Fast Track Designation by the FDA in January 2020. The drug candidate’s combination with approved products could unlock NSCLC market for patients that cannot benefit from existing therapies. Oncoprex is a first-in-class immunogene therapy, which uses a proprietary, non-viral nanoparticle to deliver tumor suppressor genes that are synergistic with cancer-killing drugs. Oncoprex works by interrupting cell signaling pathways that cause replication and proliferation of cancer cells, re-establishing pathways for apoptosis (or programmed cell death) in cancer cells and modulating the immune response against cancer cells. Oncoprex has also been shown to block mechanisms that create drug resistance. Preclinical data indicate that Oncoprex has significant cancer-killing synergy when combined with a variety of kinase inhibitors, including those targeting EGFR and AKT, and with checkpoint inhibitors. Independent researchers found that TUSC2, the active agent in Oncoprex, is a potential target and biomarker for thyroid carcinoma and could play a future role in thyroid cancer therapy. Latest corporate development is a recently signed exclusive license agreement with the University of Pittsburgh for a potentially curative gene therapy candidate for both Type 1 and Type 2 diabetes that would eliminate the need for insulin replacement therapy in diabetic patients. Genprex plans to pursue potential world-wide partnerships for the development of this therapy.